Skip to main content
. Author manuscript; available in PMC: 2023 Jul 25.
Published in final edited form as: Oncogene. 2023 Apr 8;42(21):1751–1762. doi: 10.1038/s41388-023-02684-9

Figure 6. High-risk multiple myeloma gene signatures are enriched in VQ Group B compared to VQ Group A and t-Vk12653 Vĸ*Myc cells.

Figure 6.

(A, B) GSEA plots comparing the upregulated genes in UAMS-70 gene signature between Group A (VQ-D1/D4) and Group B (VQ-D2/D5) MM cells (A) as well as between t-Vk12653 and Group B (VQ-D2/D5) cells (B). (C) EMC-92 risk scores calculated using clinical risk algorithm (see Materials and Methods) for control plasma cells, t- Vk12653 cells, and Group A and B VQ cells. Two-sided t-test with Holm Bonferroni Correction was performed. Samples are color-coded and tissues of origin for individual samples are denoted by legend. FDR, false discovery rate; NES, normalized enrichment score; ns, not significant. **, p <0.01.